...5-16 with congenital muscular dystrophy showing that once-daily 0.02-0.08 mg/kg doses of oral omigapil (SNT-317, TCH-346...
...study with regulatory authorities to determine next steps for advancing omigapil to a pivotal trial. Omigapil...
...Pharmaceuticals Holding AG (SIX:SANN), Liestal, Switzerland Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Omigapil (SNT-317, TCH-346...

...Products Grants Program to support the ongoing open-label, dose-escalation, U.S. Phase I CALLISTO trial evaluating omigapil...
...congenital muscular dystrophy. Santhera expects to complete the trial next half. Santhera has rights to omigapil...

...the open-label, dose-escalation, U.S. Phase I CALLISTO trial evaluating 0.02, 0.08 and 0.2 mg/kg/day oral omigapil...
...AG (SIX:SANN), Liestal, Switzerland Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Omigapil ( SNT-317 , TCH-346...

...of the peptide. Novartis AG and Santhera Pharmaceuticals Holding AG have omigapil ( SNT-317 ; TCH-346...

...Licensing status Publication and contact information Neurology Addiction; neurology Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) Mouse studies suggest omigapil...
...addiction or overdose. In mice, omigapil decreased cocaine-mediated neurotoxicity compared with no treatment. In mice, omigapil...
...Abuse include evaluating the anticocaine effects of omigapil in animal models. Santhera Pharmaceuticals Holding AG's omigapil...

...could be used in combination, and the company will explore this strategy in preclinical tests. Omigapil...

...treatments with highly specific and well-defined modes of action. Santhera will develop a formulation of omigapil...

...Next half, Santhera plans to start a Phase II/III trial of omigapil (SNT-317) to treat CMD...
...Santhera Pharmaceuticals AG (SWX:SANN), Liestal, Switzerland Novartis AG (NYSE:NVS; SWX:NOVN), Basel, Switzerland Product: Omigapil ( SNT-317...

...SANN received an exclusive license to develop NVS's omigapil ( SNT-317 ) to treat congenital muscular...
...remaining stock of the drug substance. SANN expects to start a Phase II trial of omigapil...